RxDoctor Payments Data

Hameed Ahmad, MD

Nephrology · Kansas City, MONPI 1144437310

Payments from drug & device makers

$526in general payments, 2019–2025

Across 15 payments — averaging $35.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$122
  • AstraZeneca$116
  • Johnson & Johnson$61
  • Bayer$53
  • Scpharmaceuticals Inc.$46
  • Vifor Pharma, Inc.$45
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$526100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$526 in reported general payments places this provider in the 40th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$111,718
Medicare patients
239
Services billed
1,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol54$58,881
JardianceEmpagliflozin16$20,944
Losartan Potassium156$1,068
Torsemide20$659
Furosemide173$623
Potassium Chloride25$606
Nifedipine ErNifedipine13$505
Calcitriol24$502
Amlodipine Besylate92$389
Chlorthalidone15$389
Lisinopril56$355
Carvedilol87$314
Tamsulosin Hcl23$260
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide18$256
Metoprolol Succinate17$190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$116$58,88154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 253 nephrology providers in Missouri.

Other nephrology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →